bioAffinity Technologies (BIAF) Free Cash Flow (2021 - 2026)

bioAffinity Technologies (BIAF) has 6 years of Free Cash Flow data on file, last reported at -$3.2 million in Q1 2026.

• Free Cash Flow for Q1 2026 came in at -$3.2 million, down 91.01% year-over-year; the trailing twelve-month figure through Mar 2026 was -$10.9 million (down 64.38% YoY), and the FY2025 annual result was -$9.4 million, down 27.85% from the prior year.
• Free Cash Flow declined to -$3.2 million in Q1 2026 per BIAF's latest filing, from -$2.6 million in the prior quarter.
• Over five years, Free Cash Flow peaked at -$376141.0 in Q2 2022 and troughed at -$3.2 million in Q1 2026.
• A 5-year average of -$1.8 million and a median of -$1.7 million in 2024 frame the typical range for Free Cash Flow.
• The sharpest annual moves came in 2023 and 2025: Free Cash Flow slumped 262.58% in 2023, then climbed 29.1% in 2025.
• A 5-year view of Free Cash Flow shows it stood at -$1.3 million in 2022, then decreased by 23.24% to -$1.6 million in 2023, then declined by 4.64% to -$1.7 million in 2024, then plunged by 52.61% to -$2.6 million in 2025, then slipped by 26.31% to -$3.2 million in 2026.
• Business Quant data shows BIAF's Free Cash Flow at -$3.2 million in Q1 2026, -$2.6 million in Q4 2025, and -$2.5 million in Q3 2025.